Search Result

Cancer CancerType Treatment Signature SearchID Experimental PMID Details Boxplot Network Correlation Survival
Triple Negative Breast CancerBRCAα-PD-1Ras-MAPK pathwayNAmouse model26515496DetailsNANANANA
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4-CD28+ T cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4-CD28- T cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4+ T helper cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4+CD25+ regulatory T cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4+ cytotoxic T cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCAc-Met RNA CAR T cellCD4+ T cellsCD4+ T cellclinical trial phase 129109077Details
Triple Negative Breast CancerBRCApoly(I:C)PD-L1CD274mouse model28848054Details
Triple Negative Breast CancerBRCApoly(I:C)CD69+/NKG2D+ CD4+ T CellNAmouse model28848054Details
Triple Negative Breast CancerBRCApoly(I:C)CD69+/NKG2D+ CD8+ T CellNAmouse model28848054Details
Triple Negative Breast CancerBRCApoly(I:C)CD69+/NKG2D+ NK CellNAmouse model28848054Details
Triple Negative Breast CancerBRCApoly(I:C)CD27- CD11b+ NK CellNAmouse model28848054Details
Triple Negative Breast CancerBRCApoly(I:C)CD27+ CD11b+ NK CellNAmouse model28848054Details
Triple Negative Breast CancerBRCAanti–PD-1 abCD69+ T cellsNAmouse model28848054Details
Triple Negative Breast CancerBRCAanti–PD-1 abCD44+CD62L+ CD8+ T cellsNAmouse model28848054Details
Triple Negative Breast CancerBRCAanti–PD-1 abIFNγ+ CD8+ T CellNAmouse model28848054Details
Triple Negative Breast CancerBLCAP53MVAp53-specific CD8+ T cellsNAclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+T cellsNaive CD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+T cellsEffector CD8+ memory T (Tem) cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+T cellsExhausted CD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+T cellsCD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+T cellsCD8+ cytotoxic T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD137+ CD8+ T cellsExhausted CD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAPD-1+ CD8+ T cellsExhausted CD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACD8+ CD103+ T cellsCD8+ T cellclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAT-betTBX21clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAEomesEOMESclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAOX40TNFRSF4clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACXCR3CXCR3clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAIFN-γIFNGclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACXCL10CXCL10clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAKLRG1KLRG1clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVACTLA-4CTLA4clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVALAG-3LAG3clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVATIM-3HAVCR2clinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVATIGITTIGITclinical trial Phase I29209571Details
Triple Negative Breast CancerBLCAP53MVAMAFMAFclinical trial Phase I29209571Details